You have 9 free searches left this month | to do more
Showing 1 - 25 of
6,196 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Not yet recruiting
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
2022-02-07
Feb 7, 2022
C
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma
Recruiting
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Determination of COVID-19 vacciantion efficacy
  • Rouen, France
    Centre Henri Becquerel
2021-06-07
Jun 7, 2021
N
Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
    The Christie NHS Foundation Trust
2022-03-15
Mar 15, 2022
A
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma - 2022
Completed
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • +2 more
  • AMG 562
  • Duarte, California
  • +11 more
2022-02-22
Feb 22, 2022
B
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) - 2020
Completed
Has Results
  • Lymphoma
  • Phoenix, Arizona
  • +44 more
2021-12-13
Dec 13, 2021
N
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
Recruiting
  • Follicular Lymphoma(FL)
  • Marginal Zone Lymphoma(MZL)
  • Nanjing, Jiangsu, China
  • +1 more
2021-01-27
Jan 27, 2021
H
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Not yet recruiting
  • CD5+ Relapsed/Refractory Hematopoietic Malignancies
  • +5 more
  • CT125A cells
  • Cyclophosphamide, fludarabine
  • (no location specified)
2021-02-19
Feb 19, 2021
X
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Recruiting
  • Lymphoma, Follicular
  • Beijing, China
  • +25 more
2022-03-03
Mar 3, 2022
C
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Enrolling by invitation
  • Relapsed/Refractory B-cell Lymphomas
  • +8 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
2021-11-30
Nov 30, 2021
C
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Recruiting
  • Relapsed/Refractory B-cell Lymphomas
  • +8 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
2021-11-30
Nov 30, 2021
T
Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
Recruiting
  • Lymphoma
  • +2 more
  • Bruxelles, Belgium
  • +30 more
2021-07-23
Jul 23, 2021
H
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) - 2020
Terminated
Has Results
  • Follicular Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Aurora, Colorado
  • +20 more
2021-12-05
Dec 5, 2021
H
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Active, not recruiting
  • Non-Hodgkin's Lymphoma
  • Tucson, Arizona
  • +22 more
2022-04-06
Apr 6, 2022
H
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - 2021
Completed
  • Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Marietta, Georgia
  • +27 more
2022-02-04
Feb 4, 2022
H
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) - 2020
Completed
Has Results
  • Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
  • Aurora, Colorado
  • +20 more
2021-04-26
Apr 26, 2021
M
ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
Recruiting
  • Lymphomas Non-Hodgkin's B-Cell
  • +5 more
  • WZTL002-1 (1928T2z CAR-T cells)
  • Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
  • Wellington, New Zealand
    Wellington Hospital, Capital & Coast District Health Board
2020-02-18
Feb 18, 2020
N
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
2022-03-25
Mar 25, 2022
M
A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML
Recruiting
  • Follicular Lymphoma (FL)
  • +6 more
  • Duarte, California
  • +10 more
2022-01-18
Jan 18, 2022
N
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL - 2018
Completed
  • Follicular Lymphoma, Mantle Cell Lymphoma
  • New York, New York
  • +6 more
2020-02-21
Feb 21, 2020
F
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Active, not recruiting
  • Relapsed Follicular Lymphoma
  • Genova, GE, Italy
  • +37 more
2021-11-11
Nov 11, 2021
H
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - 2019
Completed
Has Results
  • Lymphoma
  • Atezolizumab [TECENTRIQ]
  • +3 more
  • Los Angeles, California
  • +18 more
2020-11-30
Nov 30, 2020
E
A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat
Recruiting
  • All Malignancies
  • +11 more
  • Encinitas, California
  • +9 more
2021-12-15
Dec 15, 2021
C
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
Recruiting
  • Relapsed / Refractory Follicular Lymphoma
  • Hefei, Anhui, China
  • +40 more
2020-06-30
Jun 30, 2020
M
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Tucson, Arizona
  • +23 more
2021-12-14
Dec 14, 2021
A
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Active, not recruiting
  • Follicular Lymphoma (FL)
  • +12 more
  • Tucson, Arizona
  • +18 more
2021-06-17
Jun 17, 2021